Antithrombin is unique among the serpins in that it circulates in a native conformation that is kinetically inactive toward its target proteinase, factor Xa. Activation occurs upon binding of a specific pentasaccharide sequence found in heparin that results in a rearrangement of the reactive center loop removing constraints on the active center P1 residue. We determined the crystal structure of an activated antithrombin variant, 
Antithrombin is unique among the serpins in that it circulates in a native conformation that is kinetically inactive toward its target proteinase, factor Xa. Activation occurs upon binding of a specific pentasaccharide sequence found in heparin that results in a rearrangement of the reactive center loop removing constraints on the active center P1 residue. We determined the crystal structure of an activated antithrombin variant, N135Q S380C-fluorescein (P14-fluorescein), in order to see how full activation is achieved in the absence of heparin and how the structural effects of the substitution in the hinge region are translated to the heparin binding region. The crystal structure resembles native antithrombin except in the hinge and heparin binding regions. The absence of global conformational change allows for identification of specific interactions, centered on Glu 381 (P13), that are responsible for maintenance of the solution equilibrium between the native and activated forms and establishes the existence of an electrostatic link between the hinge region and the heparin binding region. A revised model for the mechanism of the allosteric activation of antithrombin is proposed.
Antithrombin is unique as a proteinase inhibitor because it requires allosteric activation. Its cofactor, heparin, binds antithrombin via a specific pentasaccharide domain that accounts for its anticoagulant activity. Antithrombin plays a critical role in the prevention of thrombosis by inhibiting the final two proteinases in the blood coagulation cascade, factor Xa and thrombin. The tight regulation of antithrombin involves the following: 1) maintenance of an inactive, native pool in plasma at 2.3 M; 2) localization to the vascular endothelium through binding to glycosaminoglycans; 3) conformational activation; 4) ability to undergo a massive conformational rearrangement upon reaction with proteinase; and 5) release from glycosaminoglycan upon formation of complex with proteinase. The complexity of the role of antithrombin in hemostasis is illustrated by the wide range of antithrombin mutations that lead to thromboembolic disorders (2) .
Antithrombin is a member of the serpin superfamily of serine proteinase inhibitors and maintains the overall serpin fold (3, 4) . It is thus capable of undergoing a dramatic conformational rearrangement upon attack by a cognate proteinase at position P1-P1Ј (nomenclature of Schechter and Berger (1)) where the surface-exposed reactive center loop is incorporated as strand four in the central ␤-sheet A (5). The loop-inserted form is significantly more stable than the native form of serpins (6, 7) , and it is believed that the energy required to stabilize the inhibitory complex with a proteinase is supplied from loop insertion (8) . All of the known structures of native serpins maintain a flexible, exposed reactive center loop containing a proteinase-accessible P1 side chain, with the exception of antithrombin (3, 4, 9 -14) . The reactive center loop of native antithrombin is constrained by the insertion of hinge region residues P15 and P14 as s4A, resulting in interactions between the P1 Arg side chain and the body of the serpin (Fig. 1) .
The conformation of the reactive center loop of native antithrombin is the structural basis of its marginal rate of factor Xa inhibition. The structure of pentasaccharide-bound antithrombin has recently been solved by x-ray crystallography ( Fig. 1 ) and reveals expulsion of the hinge region and secondary structural changes in the heparin binding region consisting of helix A and D elongation and helix P formation (15) . Biochemical studies have indicated that activation is ultimately the result of the reorientation of the cognate P1 Arg from interacting with the main body of the protein to pointing out toward a potential attacking proteinase (16) . The reorientation of the P1 side chain is not seen in the pentasaccharide-bound structure, presumably due to contacts between the reactive center loop of the active monomer and its latent counterpart.
Activation can also be effected by the forced expulsion of the hinge region through substitution of the P14 Ser with bulky or charged residues. This has been shown using a P14 Ser 3 Trp, which gave a 3-fold increase in rate of reaction with factor Xa (17) , and for a P14 Ser 3 Cys variant derivatized with fluorescein that was fully activated toward factor Xa (460-fold over P14-Cys control) (18) . Such variants achieve activation through a destabilization of the native state resulting in a shifting of the equilibrium position between the native and activated states (Fig. 1) . In contrast, the pentasaccharide alters the equilibrium position by stabilizing the activated state. This is borne out by thermal denaturation studies that show a 10°C increase in stability for antithrombin bound to the physiological pentasaccharide, a 20°C increase in stability for antithrombin bound to a synthetic pentasaccharide with a 100-fold higher affinity for antithrombin (19) , and an 8°C decrease in stability for the native fluorescein-labeled variant when compared with the control, P14-Cys, which itself was more than 2°C more stable than the recombinant background (18) . In all studies, the level of activation against factor Xa is dependent on the energy difference between the native and activated states.
The structures of native and pentasaccharide-bound antithrombins, as well as the biochemical studies on P14 variants, provide convincing evidence that activation requires the expulsion of the hinge region. A major question remains concerning the mechanism of allosteric activation of antithrombin. How do the local structural changes caused by pentasaccharide binding result in the expulsion of the hinge region from ␤-sheet A? It was hypothesized by van Boeckel and colleagues (20) , based on the structure of native antithrombin and computer simulations, that binding of the pentasaccharide occurred at the C terminus of helix D and that expulsion of the reactive center loop resulted from a mechanical force effected on strand 2A by the C-terminal elongation of helix D. The structure of pentasaccharide-bound antithrombin revealed both helix D elongation and loop expulsion but not, as proposed, through direct interaction between the elongated portion of helix D and the pentasaccharide. This leaves the question of how pentasaccharide binding causes expulsion of the hinge region from ␤-sheet A. We hypothesize that the D-helix elongation is a consequence of the electrostatic effect of pentasaccharide binding and that expulsion is not effected by a mechanical force but rather a perturbation of surface electrostatics that help determine the equilibrium position between the native and activated forms. This hypothesis is tested here by determining the structure of an antithrombin variant, N135Q, S380C, that is fully activated in solution in the absence of pentasaccharide due to the presence of a bulky fluorescein moiety bound at the P14 position (18) . We specifically address the questions of how the solution equilibrium between the native and activated states is maintained and how remote binding of the pentasaccharide confers its effect on the conformation of the reactive center loop.
EXPERIMENTAL PROCEDURES
Protein Expression and Derivatization-The S380C variant of antithrombin was produced on the recombinant ␤-glycoform antithrombin template of N135Q, as described previously (17) , in order to reduce heparin binding heterogeneity. The variant was then reacted with 5-iodoacetamidofluorescein, obtained from Molecular Probes, Eugene, OR, on a 1-ml heparin-Sepharose column with a continuous loop run overnight at room temperature. After washing with low salt buffer (20 mM Tris, 10 mM sodium citrate, 5 mM EDTA, pH 7.4), the derivatized variant was eluted with a NaCl gradient as a single peak at about 1.7 M NaCl. The pooled fractions were 76% labeled, based on differential absorbance at 280 and 494 nm, and buffer-exchanged into 10 mM Tris, pH 7.4.
Crystallization-Crystallization was achieved as described previously (15, 21) . Briefly, equimolar amounts of the derivatized or underivatized variant and previously prepared plasma latent antithrombins were mixed with a concentrated solution of the precipitant in a 10-well glass plate. Final concentrations were 5 mg/ml protein, 10.5% PEG 1 4000, 65 mM sodium cacodylate, pH 6.5. Crystals grew within 2 weeks of mixing and were yellow/green for the fluorescein-labeled variant.
Data Collection and Processing-Diffraction data were collected at the SRS Daresbury, UK, on beamline 7.2 for P14-fluorescein and 9.6 for the P14-Cys control using a single frozen crystal of each. Cryoprotection for the P14-fluorescein variant crystal was effected by quickly dipping the crystal into a solution of 10% methylpentanediol, 15% glycerol, 10.5% PEG 4000, 100 mM cacodylate, pH 6.5, and quick freezing in the cryostream at 100 K. The control crystal, P14-Cys, was dehydrated in 20% PEG 4000 and the cryoprotected with 20% glycerol. Useful data were obtained to a resolution limit of 2.85 and 2.8 Å for P14-fluorescein and P14-Cys, respectively, and processed using the programs of the CCP4 suite (22) .
Molecular Replacement and Refinement-A cross-rotation function was computed using the program AMoRe (23) from the CCP4 package using the structure of the dimer of the ␤-isoform of plasma antithrombin as the search model. 2 Iterative rounds of rebuilding and refinement were conducted using the programs O (24) and Refmac (25) using the bulk solvent correction of CNS (35) . Statistics of the final models are described in the Table I . Figures were made using Molscript (26), Bobscript (27) , Grasp (28) , and Raster3D (29, 30) .
Structural Comparison-All comparisons were between the structure of the ␣-glycoform of plasma antithrombin (31) at 2.6-Å resolution that had been refined further using the programs Refmac and CNS. 3 This structure was chosen over the P14-Cys for comparison with the P14-fluorescein structure due to its higher resolution and better electron density in the regions of interest. 4 
RESULTS
Description of the Structure-Crystallization of the P14-fluorescein variant was facilitated by the addition of equimolar amounts of the latent conformer of plasma antithrombin (15, 21) . Thus the asymmetric unit consists of an active/latent dimer, as in all other crystal structures of antithrombin (3, 15, 21, 31) , in which the reactive center loop of the active monomer replaces s1C of its latent partner. The C␣ trace of the dimer of P14-fluorescein and latent plasma antithrombins is given in Fig. 2a . Although the biochemical activity of the variant indicated that the fluorescein at position P14 induced a full conversion to the activated conformation, the structure was found to be in the partially inserted form as in native antithrombin.
FIG. 1. Ribbon diagrams of native and pentasaccharide-bound
antithrombins. The central ␤-sheet A is in red; the reactive center loop is in yellow; helix D is in cyan; helix A is in green; and the P1 arginine in red space filling. The secondary structural changes in the pentasaccharide bound structure are in yellow, and the pentasaccharide is in a ball-and-stick representation. Glycosaminoglycan binding occurs via two steps as follows: the first step is dependent on the concentration of the glycosaminoglycan, and the second step, involving the forward rate of conformational change, k 2 , and the reverse rate, k Ϫ2 , is independent. Activation ultimately depends on release of constraints on the P1 Arg side chain allowing for its orientation away from the body of antithrombin. This is achieved, presumably, by expulsion of the hinge region. The pentasaccharide bound structure shows P1 Arg in the inactive orientation due to crystal contacts in the reactive center loop between P3 and P8. The position of the equilibrium at saturating concentrations of glycosaminoglycan determines its level of activation. The equilibrium in the absence of glycosaminoglycan is reversed, with
This is most likely due to the difference in environment between solution and crystal and the constraints imposed by the formation of the dimer. The long and flexible linker allowed for the accommodation of the bulky fluorophore on the surface of ␤-sheet A with minimal perturbation of the backbone conformation for residues 378, 379, and 380 (P16 to P14). Fig. 2b is an electron density map of the region surrounding the fluorescein moiety and clearly demonstrates its position. The overall C␣ r.m.s. deviation for the residues from 40 to 431 between the P14-fluorescein and plasma antithrombins was 0.936 Å, with the core of the molecule essentially unchanged. Comparison with the structure of native plasma antithrombin reveal two regions that have been significantly perturbed by the fluorescein as follows: the hinge region, of which the fluorescein labeled cysteine is a part, and the heparin binding region. Fig. 2c is a ribbon diagram of P14-fluorescein illustrating the secondary structural changes in the heparin binding region, and Hinge Region Interactions-Central to the question of what confers the special properties of antithrombin is the issue of why, in contrast to other serpins, the native conformation has its hinge region inserted in ␤-sheet A. The fully activated properties of P14-fluorescein antithrombin indicate that it exists predominantly in the loop-expelled conformation in solution. From this it is concluded that the fluorescein adduct is responsible for the change in position of the solution equilibrium. We therefore focused on the hinge region interactions that are perturbed by the fluorescein, and we identified a network of interactions in native antithrombin centered about Glu 381 (P13), which forms a bridge between the hinge region, the helix F loop, and strands three and five of ␤-sheet A, which are altered in the P14-fluorescein structure. Fig. 3 374 . These interactions are perturbed by the presence of the fluorescein moiety in the P14-fluorescein variant that replaces the side chain position of the P13 Glu in the native structure and forces its reorientation toward the position occupied in the pentasaccharide-activated conforma- 
The free set of reflections was selected to be the same as the free set used for the refinement of ␣-antithrombin and ␤-antithrombin. e R-factor ϭ ¥ hkl ͉͉F obs ͉ Ϫ ͉F calc ͉͉/¥ hkl ͉F obs ͉. f Residues glycosylated and found in the same conformation in the latent and inhibitory forms of ␣-antithrombin. and Lys 222 of s2A and s3A, respectively. P13 Glu in the fluorescein variant shifts similarly due to the presence of the fluorescein group at P14 into close proximity to Lys 139 but without making a hydrogen bond. The effect of the reorganization of the charged residues constituting the network surrounding P13 Glu is an alteration of the surface electrostatic potential of antithrombin (Fig. 4) .
Structure of the Heparin Binding Domain-As Fig. 2c demonstrates, there is a change in secondary structure in the heparin binding region similar to that found in the pentasaccharide-bound antithrombin. The P14-fluorescein variant was made on the recombinant ␤ template N135Q which prevents glycosylation at this position. We observed the presence of a hydrogen bond between Gln 135 and a main chain N on s2A. To ensure that the altered helix D conformation for the P14-fluorescein variant was not due to the N135Q background, we also crystallized and solved the structure of the S380C,N135Q variant in the absence of fluorescein. As Fig. 5 demonstrates, the conformation of the recombinant control more closely resembles that of glycosylated plasma antithrombin with a surface-exposed side chain at position 135. This confirms that the structural changes in helix D of P14-fluorescein are the result of the presence of the fluorescein adduct in the hinge region.
Recent attention has been drawn to the potential role of helix A elongation in the mechanism of activation of antithrombin. Clearly, residues Arg 46 and Arg 47 are involved in the binding of heparin but are not critical (34) . Surprisingly, our control structure of P14-Cys showed the same helix A elongation as the fluorescein-derivatized variant, extending to Asn 45 as in the pentasaccharide-bound antithrombin. In addition, the structure of latent antithrombin in complex with the pentasaccharide shows both helix A elongation and helix P formation identical to the pentasaccharide-bound active monomer, but no elongation of helix D is observed (15) . It therefore seems likely that helix A elongation and helix P formation facilitate tight interaction with the pentasaccharide but are not involved in the transmission of conformational change to the hinge region. Fig. 2d demonstrates that, in addition to secondary structural changes in the heparin binding region, the presence of the fluorescein perturbs the conformation of the side chains on the surface of the variant. Interestingly, these limited changes form a link between the fluorescein moiety in the hinge region and the heparin binding region. The surface electrostatic potentials of the plasma and P14-fluorescein antithrombins oriented as in Fig. 2d are given in Fig. 4 . Here too, the conformational link between the two regions is evident. More importantly, this comparison demonstrates that the effect of the perturbation of the interactions in the hinge region results in long range surface potential changes in the heparin binding region.
DISCUSSION
Regulation of antithrombin activity through binding to heparin-like oligosaccharides depends on a native fold which is kinetically inactive toward its target proteases. Therefore, how the native conformation is maintained and how heparin binding results in activation are central to understanding the special role antithrombin plays in the coagulation pathway. The structure of the P14-fluorescein variant of antithrombin described here directly addresses these issues. Interpretation of the structure in terms of the mechanism of activation requires a two-state model where the degree of activation depends on the position of the equilibrium between the two states, native and activated. The native state has a six-stranded ␤-sheet A due to the incorporation of the hinge region residues P15 and P14 as s4A, and the activated state has a five-stranded ␤-sheet A and resembles all of the other known structures of native serpins. Activation is normally achieved by the binding of a specific pentasaccharide sequence that stabilizes the fivestranded form resulting in its dominating the solution equilibrium. Due to the large structural changes accompanying pentasaccharide binding, the structures of the native and pentasaccharide-bound states are not alone sufficient for identification of the interactions that stabilize the native state in the absence of oligosaccharide. We crystallized the P14-fluorescein variant in a state that represents the left-hand side of the solution equilibrium illustrated in Fig. 1 . This allows for the identification of the hinge region interactions involved in stabilizing the native conformation, since they would necessarily be altered by the presence of the fluorescein adduct.
We identified a network of electrostatic interactions centered on the P13 Glu which acts as a bridge between the overlying helix F loop, the hinge region, and flanking strands 3 and 5 of ␤-sheet A. These interactions are undone by the presence of the fluorescein in the structure of the variant. From the biochemical characterization of the variant, it is possible to conclude that disruption of this network alone is sufficient for the shift in equilibrium to favor the five-stranded activated state. The major conformational change caused by the presence of the fluorescein moiety was the shifting of the P13 Glu toward the heparin binding region. It is important to note that the P13 side chain could have moved elsewhere but was found oriented toward the heparin binding region in a position similar to that found in the pentasaccharide-bound structure. We believe that the observed change in side chain orientation of the P13 Glu represents a critical step in the activation mechanism first by no longer participating in the network of interactions responsible for stabilizing the native state, and second by shifting toward the heparin binding region.
We also observed changes in the conformation of the heparin binding region in the P14-fluorescein variant. These changes resemble those observed in the presence of the pentasaccharide but are not identical. This finding is of interest since it links changes in the hinge region with the heparin binding region. The space filling model given as Fig. 2d demonstrates that the conformational changes induced by the fluorescein in the hinge region are propagated to the heparin binding region, and the surface potential maps in Fig. 4 demonstrate how the two regions are linked through electrostatics. We do not see evidence of a discrete network of hydrogen bonding interactions linking the two regions in the structure of P14-fluorescein, rather, we observe a more subtle effect of charged surface side chains affecting the orientation of others nearby which hinges on the orientation of the P13 Glu side chain. This is in contrast to the mechanistic model for the transmission of conformational change proposed by van Boeckel and colleagues (20) .
These results, taken together with recent investigations into the binding of truncated pentasaccharides (32, 33) , allow for the proposal of a more detailed model of glycosaminoglycan activation of antithrombin as follows. 1) Antithrombin exists in an equilibrium between the kinetically inactive, six-stranded, and the activated, five-stranded, conformations defined by k 2 / k Ϫ2 (Fig. 1) . The extent of activation upon gylcosaminoglycan binding, at saturation, is related to the strength of binding defined by k 2 /k Ϫ2 . 2) Glycosaminoglycan binding changes the surface electrostatic network that links the heparin-binding site and the reactive center loop so as to alter the interactions of P13 Glu that stabilize the loop-inserted conformation in the native state.
3) The pentasaccharide-induced change in surface electrostatics has two components. One is that pentasaccharide residues D, E, and F bind to helix D and increase k 2 through charge neutralization and helix D elongation. The second is that the bound state is stabilized, decreasing k Ϫ2 , through interactions between pentasaccharide residues G and H and Arg 46 and Arg 47 on the N terminus of helix A. Efforts to create activated antithrombin variants for replacement therapy can now be focused on the interactions made by the P13 Glu residue. Destabilization of these interactions or stabilization of the activated conformer should result in a constitutively activated antithrombin.
